Consumer medicine information

Ultratag RBC

Technetium (99mTc)-labelled red blood cells

BRAND INFORMATION

Brand name

Ultratag RBC

Active ingredient

Technetium (99mTc)-labelled red blood cells

Schedule

Unscheduled

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Ultratag RBC.

What is in this leaflet

This leaflet answers some of the common questions about Ultratag RBC. It does not contain all of the available information about Ultratag RBC. It does not replace talking to your doctor.

All medicines have risks and benefits. Your doctor has weighed the risks of you or your child receiving Ultratag RBC against the benefits he or she expects it will have.

If you have any concerns about having this medicine, ask your doctor.

Keep this leaflet. You may need to read it again.

What is Ultratag RBC

Ultratag RBC is a kit consisting of 3 separate components which are used in combination to prepare radiolabeled red blood cells. Ultratag RBC belongs to a group of medicines called radiopharmaceutical agents, which are all radioactive.

Ultratag RBC comes as a kit containing a 10 mL reaction vial and 2 syringes. There are 5 units in a multi-dose kit.

What is Ultratag RBC used for

Ultratag RBC is an imaging agent that is used primarily in cardiac function studies. Ultratag RBC is also used in detecting sites of gastrointestinal bleeding.

Your doctor may have prescribed Ultratag RBC for another purpose. Ask your doctor if you have any questions about why Ultratag RBC has been prescribed for you. If you have any concerns, you should discuss these with your doctor.

This medicine is only available with a doctor’s prescription.

Before you are given Ultratag RBC

Before you are given Ultratag RBC, your doctor will explain to you the procedure you are about to undergo, and the radioactive medicine you will be given. You must discuss any concerns you have with your doctor.

Ultratag RBC is recommended for patients 18 years of age and older. If your doctor believes it is necessary to give Ultratag RBC to a patient under 18, he or she will discuss the benefits and risks with you.

You must tell your doctor if you have allergies to:

  • any other medicines
  • any other substances such as foods, preservatives or dyes

Tell your doctor if you are or plan to become pregnant. Like most medicines, Ultratag RBC is not recommended for use during pregnancy. If there is a need to consider Ultratag RBC during your pregnancy, your doctor will discuss the benefits and risks of giving it to you.

Tell your doctor if you are breast feeding or plan to breast feed. Like most medicines, Ultratag RBC is not recommended while you are breast feeding. However, if you are breast feeding, formula feedings should be substituted for breast feeding for 24 hours following the administration of Ultratag RBC. Breast milk produced within that time should be discarded.

Tell your doctor if you have any other medical conditions.

Taking other medicines

Tell your doctor if you are taking any other medicines, including medicines that you buy without a prescription from your pharmacy, supermarket or health food shop.

How Ultratag RBC is given

How much is given

Your doctor will decide how much you will be given. This depends on your condition and other factors, such as weight.

How it is given

Ultratag RBC is given as an injection into a vein. UltraTag RBC should only be given by a doctor or a nurse.

When you are given Ultratag RBC

Things you must do

There is nothing in particular you must do once given Ultratag RBC.

Things you must not do

Do not take any other medicines unless advised by your doctor.

Things to be careful of

To minimise the radiation dose to the bladder, drink fluids and void immediately before the examination and as often thereafter as possible for the next 4 to 6 hours.

Side effects

Tell your doctor as soon as possible if you do not feel well after being given Ultratag RBC. All medicines have side effects. Sometimes they are serious, most of the time they are not. You may need medical treatment if you get some side effects.

Tell your doctor if you experience any side effects which worry you.

Product description

What it looks like

Ultratag RBC is supplied as a kit containing a 10 mL reaction vial and 2 syringes. An injection is prepared from withdrawing a sample of the patient’s blood, transferring the sample to the 10 mL reaction vial, adding the contents of syringe I and syringe II to the reaction vial and dispensing technetium (99mTc). The contents in the reaction vial will be mixed for approximately 20 minutes.

Ingredients

Active ingredients:

10 mL Reaction Vial:

  • stannous chloride dihydrate - 50 μg minimum (96 μg theoretical)

Inactive ingredients:

10 mL Reaction Vial:

  • sodium citrate dihydrate - 3.67 mg
  • Glucose – 5.5 mg

Syringe I (0.6 mL):

  • sodium hypochlorite - 0.6 mg
  • water for injection - qs

Syringe II (10 mL):

  • citric acid monohydrate - 8.7 mg
    sodium citrate dihydrate - 32.5 mg
    glucose – 12 mg
    water for injection - qs

This medicine does not contain lactose, sucrose, gluten, tartrazine or any other azo dyes.

Sponsor

Landauer Radiopharmaceuticals Pty Ltd
Level 3/69 Phillip Street
Parramatta NSW 2015
Australia

Manufactured by Curium US LLC
Made in USA

Registration Number: AUST R 47860

This leaflet was prepared in February 2023.

Published by MIMS April 2023

BRAND INFORMATION

Brand name

Ultratag RBC

Active ingredient

Technetium (99mTc)-labelled red blood cells

Schedule

Unscheduled

 

1 Name of Medicine

Stannous chloride dihydrate.

2 Qualitative and Quantitative Composition

Ultratag RBC Kit for the preparation of technetium Tc 99m-labelled red blood cells, a diagnostic radiopharmaceutical agent.
Ultratag RBC is a sterile, non-pyrogenic, diagnostic kit for the in vitro preparation of technetium Tc 99m-labelled red blood cells.
Each kit consists of three separate non-radioactive components. A reaction vial containing the active ingredient stannous chloride dihydrate, the contents of the vial are lyophilised and stored under argon. There are two syringes containing diluent solutions for reconstitution.
For the full list of excipients, see Section 6.1 List of Excipients.

Physical characteristics.

Technetium Tc 99m decays by isomeric transition with a physical half-life of 6.02 hours.1 The principal photon that is useful for detection and imaging is listed in Table 1.
The specific gamma ray constant for technetium Tc 99m is 0.78 R/mCi-hr at 1 cm. The first half-value thickness of lead (Pb) for technetium Tc 99m is 0.017 cm. A range of values for the relative attenuation of the radiation emitted by this radionuclide resulting from the interposition of various thicknesses of lead (Pb) is presented in Table 2. For example, the use of 0.25 cm of lead will decrease the external radiation exposure by a factor of about 1000.
To correct for physical decay of the radionuclide, the fractions that remain at selected time intervals after the time of calibration are shown in Table 3.

3 Pharmaceutical Form

Reaction vial.

Powder for injection.
White lyophilised powder.

Syringe I.

Diluent, clear colourless liquid.

Syringe II.

Diluent, clear colourless liquid.

4 Clinical Particulars

4.1 Therapeutic Indications

Technetium Tc 99m-labelled red blood cells are used for blood pool imaging, including cardiac first pass and gated equilibrium imaging and for detection of sites of gastrointestinal bleeding.

4.2 Dose and Method of Administration

Dosage.

The suggested dose range of technetium Tc 99m-labelled red blood cells in the average patient (70 kg) is 370 MBq (10 mCi) to 740 MBq (20 mCi).
The patient dose should be measured by a suitable radioactivity calibration system immediately prior to administration.

Radiation dosimetry.

The estimated radiation doses to an average adult (70 kg) from an intravenous injection of a maximum dose of 740 megabecquerel (MBq) (20 millicurie [mCi]) of technetium Tc 99m-labelled red blood cells are shown in Table 4.
These radiation absorbed dose values were calculated using the medical internal radiation dose (MIRD) committee schema.

Method of administration.

The instructions for preparation must be carefully followed for preparing Technetium Tc 99m-labelled red blood cells using Ultratag RBC.
Parenteral products should be inspected visually for particulate matter and discolouration prior to administration, whenever solution and container permit. Aseptic procedures and a shielded syringe should be employed in preparing and withdrawing doses for administration to patients. The user should wear waterproof gloves during the administration procedure.
It is recommended that the labelled red blood cells be administered within 30 minutes of preparation or as soon as possible thereafter.

Procedure for the preparation of technetium Tc 99m-labelled red blood cells

1. Collect patient's blood sample (1.0 to 3.0 mL) using heparin or anticoagulant citrate dextrose solution (ACD) as an anticoagulant. The amount of ACD should not exceed 0.15 mL of ACD per mL of blood. The recommended amount of heparin is 10 to 15 units per mL of blood. Do not use EDTA or oxalate as an anticoagulant.
2. Using a large-bore (19 to 21 gauge) needle, transfer 1.0 to 3.0 mL of anticoagulated whole blood to the reaction vial and gently mix to dissolve the lyophilised material. Allow to react for five minutes.
3. Add contents of syringe I, mix by gently inverting four to five times.
4. Add the contents of syringe II to the reaction vial. Mix by gently inverting four to five times.
5. Place the vial in a lead shield fitted with a lead cap and having a minimum wall thickness of 3 mm. Add 370 to 3700 MBq (10 to 100 mCi) sodium pertechnetate Tc 99m (in a volume of up to 3 mL) to the reaction vial. The avoidance of long technetium Tc 99m in-growth times and the use of fresh sodium pertechnetate Tc 99m generator eluate is recommended.
6. Mix by gently inverting reaction vial four to five times. Allow to react for 20 minutes with occasional mixing.
7. Technetium Tc 99m-labelled red blood cells should be injected within 30 minutes of preparation or as soon as possible thereafter.
8. If desired, assay labelling efficiency immediately prior to injection. Typical labelling efficiency is greater than 95%.
9. Mix gently prior to withdrawal of patient dose. Aseptically transfer the technetium Tc 99m-labelled red blood cells to a syringe for administration to the patient. Use largest bore needle compatible with patient administration to prevent hemolysis.
10. Assay the technetium Tc 99m-labelled red blood cell patient dose in a suitable calibrator and complete the radioassay information label. Affix the radioassay information label to the shield.

Note 1.

The kit does not contain an anticoagulant. Therefore, a syringe treated with ACD or heparin must be used for drawing the patient's blood. The amount of ACD should not exceed 0.15 mL of ACD per mL of blood. The recommended amount of heparin is 10 to 15 units per mL of blood. Improperly anticoagulated blood will be unsuitable for reinjection.

Note 2.

If desired, the labelling yield determination can be carried out as follows:
Transfer 0.2 mL of the technetium Tc 99m-labelled red blood cells to a centrifuge tube containing 2 mL of 0.9% NaCl. Centrifuge for five minutes and carefully pipet off the diluted plasma. Measure the radioactivity in the plasma and red blood cells separately in a suitable counter.
Calculate labelling efficiency as follows:

4.3 Contraindications

None known.

4.4 Special Warnings and Precautions for Use

The components of the kit are sterile and nonpyrogenic. It is essential that the user follow the directions carefully and adhere to strict aseptic procedures during preparation.
The contents of the kit are intended only for use in the preparation of technetium Tc 99m-labelled red blood cells and are not to be administered directly to the patient.
The contents of this kit are not radioactive. After sodium pertechnetate Tc 99m is added, however, adequate shielding of the final preparation must be maintained.
Technetium Tc 99m-labelled red blood cells must be handled with care to ensure minimum radiation exposure to the patient, consistent with proper patient management, and to ensure minimum radiation exposure to occupational workers.
The labelled red blood cells must be reinjected only into the patient from whom the blood was drawn.
Nuclear medicine procedures involving withdrawal and reinjection of blood have the potential for transmission of blood borne pathogens. Procedures should be implemented to avoid administration errors and viral contamination of personnel during blood product labelling. A system of checks similar to the ones used for administering blood transfusions should be routine.
It is recommended that the labelled red blood cells be administered within 30 minutes of preparation or as soon as possible thereafter. A small study showed that technetium Tc 99m-labelled red blood cells prepared with Ultratag RBC have equivalent in vivo labelling efficiency when administered both immediately after preparation (5 patients studied) and at 6 hours after preparation (6 patients studied) with a 24-hour labelling efficiency averaging 97% for both groups.
Radiopharmaceuticals should be used only by physicians who are qualified by specific training in the safe use and handling of radionuclides and whose experience and training have been approved by the appropriate government agency authorised to license the use of radionuclides.

Use in the elderly.

There is no special safety or dosage information available for use in the elderly.

Paediatric use.

Safety and efficacy in paediatric patients have not been established.

Effects on laboratory test.

This information is not available.

4.5 Interactions with Other Medicines and Other Forms of Interactions

Clinical trials were conducted with a variety of prescription and nonprescription medications and showed no significant effect on the in vitro labelling efficiency of Ultratag RBC. Unlike stannous pyrophosphate red blood cell kits, heparinised patients (11) showed minimal interference with Ultratag RBC labelling efficiency (95% with heparin, 97% without heparin).

4.6 Fertility, Pregnancy and Lactation

Effects on fertility.

This information is not available.
Animal reproduction studies have not been conducted with technetium Tc 99m-labelled red blood cells. It is also not known whether this medicine can cause foetal harm when administered to a pregnant woman or can affect reproductive capacity. Technetium Tc 99m-labelled red blood cells should be administered to a pregnant woman only if clearly needed. Ideally, examinations using radiopharmaceuticals, especially those elective in nature, of a woman of childbearing capability should be performed during the first few (approximately 10) days following the onset of menses.
 Technetium Tc 99m is excreted in human milk during lactation, therefore, formula feedings should be substituted for breast feeding.

4.7 Effects on Ability to Drive and Use Machines

The effects on ability to drive and use machines were not assessed as part of its registration.

4.8 Adverse Effects (Undesirable Effects)

None known.

Reporting suspected adverse effects.

Reporting suspected adverse reactions after registration of the medicinal product is important. It allows continued monitoring of the benefits-risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at www.tga.gov.au/reporting-problems.

4.9 Overdose

In the event of the accidental administration of an overdose of the radiopharmaceutical very little supportive treatment can be undertaken since its elimination is entirely dependent on the normal haemolytic process. Forced diuresis and frequent bladder voiding are recommended in the case of overdose with Tc 99m pertechnetate.
For information on the management of overdose, contact the Poisons Information Centre on 131126 (Australia).

5 Pharmacological Properties

5.1 Pharmacodynamic Properties

Mechanism of action.

No data available.

General.

In vitro Tc 99m red blood cell labelling is accomplished by adding 1.0 to 3.0 milliliters of autologous whole blood, anticoagulated with heparin or anticoagulant citrate dextrose solution (ACD), to the reaction vial. A portion of the stannous ion in the reaction vial diffuses across the red blood cell membrane and accumulates intracellularly. The in vitro Tc 99m red blood cell labelling efficiency can decrease in the presence of excess ACD. Excess ACD apparently impairs the diffusion of stannous ion across the red blood cell membrane. Therefore, the ACD concentration used for blood collection should not exceed 0.15 mL ACD per mL of blood. Sodium hypochlorite is then added to the reaction vial to oxidise the extracellular stannous ion. Since the hypochlorite does not cross the red blood cell membrane, the oxidation of stannous ion is selective for the extracellular tin. A citric acid, sodium citrate and dextrose solution is then added to the reaction vial to sequester any residual extracellular stannous ion, rendering it more readily available for oxidation by sodium hypochlorite.
Radioactive labelling of the red blood cells is completed by addition of sodium pertechnetate Tc 99m to the oxidised reaction vial. The pertechnetate Tc 99m diffuses across the red blood cell membrane and is reduced by the intracellular stannous ion. The reduced technetium Tc 99m cannot diffuse out of the red blood cell. The red blood cell labelling is essentially complete within 20 minutes of sodium pertechnetate Tc 99m addition to the reaction vial. Red blood cell labelling efficiency of ≥ 95% is typically obtained using this in vitro labelling procedure. In vitro Tc 99m red blood cell labelling efficiency can decrease when excessive amounts of Tc 99m are allowed to accumulate in the sodium pertechnetate Tc 99m generator eluate; in this situation, efficiency decreases even further if excess (i.e. > 0.15 mL per mL of blood) ACD buffer is used. Therefore, long Tc 99m in-growth times are to be avoided; the use of fresh (≤ 24 hour in-growth time) sodium pertechnetate Tc 99m generator eluate is recommended. After the labelling procedure is completed, the technetium Tc 99m-labelled red blood cells are then reinjected intravenously into the patient for gamma scintigraphic imaging.

Clinical trials.

No data available.

5.2 Pharmacokinetic Properties

Distribution.

Following intravenous injection, the technetium Tc 99m-labelled red blood cells distribute within the blood pool with an estimated volume of distribution of approximately 5.6% of body weight. The technetium Tc 99m is well retained in the blood pool with an estimated biological half-life of approximately 29 hours. Of the total technetium Tc 99m retained in the whole blood pool 24 hours after administration, 95% remains bound to the red blood cells.

5.3 Preclinical Safety Data

Genotoxicity.

No data available.

Carcinogenicity.

No long term animal studies have been performed to evaluate carcinogenic or mutagenic potential or to determine the effects on male or female fertility.

6 Pharmaceutical Particulars

6.1 List of Excipients

Reaction vial.

Glucose, sodium citrate dihydrate.

Syringe I.

Sodium hypochlorite, water for injections.

Syringe II.

Citric acid monohydrate, glucose, sodium citrate dihydrate, water for injections.

6.2 Incompatibilities

Incompatibilities were either not assessed or not identified as part of the registration of this medicine.

6.3 Shelf Life

Before reconstitution.

15 months from date of manufacture.

After reconstitution.

Inject within 30 minutes of preparation where possible. Use within 6 hours of preparation.

6.4 Special Precautions for Storage

Before reconstitution.

Kit.

Stored below 25°C. Protect from light. Do not freeze.

Reaction vial.

Stored below 25°C. Do not freeze.

Syringe I.

Stored below 25°C. Protect from light. Do not freeze.

Syringe II.

Stored below 25°C. Do not freeze.

After reconstitution.

Stored below 25°C. Do not freeze.

6.5 Nature and Contents of Container

Each pack contains 5 kits.
Each kit contains: 1 x reaction glass vial; 1 x glass syringe I; 1 x glass syringe II.

6.6 Special Precautions for Disposal

In Australia, any unused medicine or waste material should be disposed of in accordance with local requirements.

6.7 Physicochemical Properties

Chemical structure.

Stannous chloride dihydrate has the following structural formula:

CAS number.

CAS number for stannous chloride dihydrate: 10025-69-1.

7 Medicine Schedule (Poisons Standard)

Not scheduled. Not considered by committee.

Summary Table of Changes